United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, UBS Group Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price objective lifted by stock analysts at UBS Group from $580.00 to $600.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price objective suggests a potential upside of 33.66% from the stock’s previous close.

UTHR has been the topic of a number of other research reports. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Wednesday, October 29th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of United Therapeutics in a report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $503.90.

United Therapeutics Stock Performance

UTHR opened at $448.91 on Thursday. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $479.50. The company has a market capitalization of $19.33 billion, a P/E ratio of 17.01, a P/E/G ratio of 4.96 and a beta of 0.77. The stock has a fifty day moving average of $423.96 and a 200-day moving average of $343.56.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the previous year, the business posted $6.39 earnings per share. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. On average, equities research analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $448.25, for a total value of $1,793,000.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $58,272.50. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 412,935 shares of company stock worth $173,677,147. 10.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics in the second quarter valued at approximately $29,000. Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics during the third quarter worth $44,000. SVB Wealth LLC acquired a new position in shares of United Therapeutics during the first quarter worth $32,000. Finally, WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.